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Objectives:  The  French  Society  of  ORL  set  up  a work  group  to draw up a consensus  document  on the
prescription  of nebulization  in  rhinology.  The  document  deals  with  the  principles  of  and  indications  for
rhinologic  aerosol  therapy.
Materials  and methods:  The  work  group’s  methodology  followed  the  rules  published  by  the  French
health  authority  (Haute  Autorité  de  santé  [HAS])  in  January  2006:  “Methodological  foundations
for  drawing  up  professional  guidelines  by formalized  consensus”  (available  on  the  HAS website  at
http://www.has-sante.fr).  The  method  used  is the  short  version  (without  editorial  group)  of  the
RAND/UCLA  Appropriateness  Method;  the  short  version  was  chosen  because  this  particular  consensus
conference  was  dealing  with  a very  precise  topic  with  very  few  experts  in  the  ﬁeld.
Results:  Sonic  aerosol  therapy  with nasal  plug  is  the  preferred  modality,  delivering  treatment  into  the
middle  meati.  The  group  recommends  that  drugs  with  market  authorization  for use  in  bronchopulmonary
pathology  should  be nebulized  in two 10-minute  sessions  per day  for at least  seven  days.  Indications  for
rhinologic  aerosol  therapy  are: purulent  edematous  rhinosinusitis,  subacute  rhinosinusitis  (4–12  weeks’
evolution),  exacerbations  of  chronic  rhinosinusitis,  and  postoperative  (>1 month)  rhinosinus  suppuration.
Audiometric  monitoring  is  required  in iterative  aminoside  nebulization.
Conclusion:  Rhinologic  aerosol  therapy  can  be  used  in  purulent  edematous  rhinosinusitis,  subacute  rhi-
nosinusitis,  exacerbations  of chronic  rhinosinusitis  and  postoperative  rhinosinus  suppuration.  The rules
for  prescription  contained  in  the present  document  optimize  efﬁcacy.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.. Introduction
Nebulization is a widely used means of drug delivery to the
pper and lower airways. Its theoretic advantage over classic means
f delivery is that it directly reaches the target organ, avoiding
ystemic side effects and enhancing local efﬁcacy. It is mainly
sed in pneumology; pneumologic nebulization shows proven efﬁ-
acy for drugs such as bronchodilators, corticosteroids, mucolytics
∗ Corresponding author.
http://dx.doi.org/10.1016/j.anorl.2014.07.004
879-7296/© 2014 Elsevier Masson SAS. All rights reserved.and antibiotics. The number of specialties in which lower-airway
nebulization has market authorization and the number of studies
published on the subject testify to the liveliness of the ﬁeld. Few
publications, however, have been devoted to ENT nebulization, and
only one drug (gomenol) has market authorization here. On the
other hand, the NUAGES survey of the use and perspectives of neb-
ulization in general and specialized medicine (nébulisation, usages
et avenir en médecine générale et spécialisée), performed in France
in 2005, clearly showed that prescription of nebulization is most
widespread in pneumology with ENT coming a very close second,
89% of ENT physicians prescribing aerosol therapies by nebuliza-
tion [1]. While there are no guidelines for ENT nebulization, the
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UAGES survey revealed practitioners’ interest in and actual use of
t. The consensus document requested by the SFORL aims to draw
p guidelines as an aid to prescription of ENT nebulization.
. Theoretic foundations and aerosol deposition
Aerosols are deﬁned in physical terms as a system of particle sus-
ension in gas. In medical aerosols, particle size is of the order of a
icrometer. The aerosols produced by different generation systems
ave particles of differing sizes. Two main parameters describe
article size distribution: mass median aerodynamic diameter
MMAD) represents median particle size; and geometric standard
eviation represents the scatter around the MMAD. The main phys-
cal mechanisms determining particle deposition in the airway are
irectly governed by particle size [2]. In nasal inhalation, larger
articles are mainly deposited in the upper airway: 90% for 10 m
articles, 50% for 5 m and 10% for 2 m [3,4]. On entering the
ostrils, the aerosol is intercepted by the vibrissae, which consti-
ute a ﬁrst large particle ﬁlter. The nasal valve, where upper airway
iameter is smallest and air-speed highest, is the site of maximal
eposition [3]. The turbinate region is the second most impor-
ant bottleneck inducing deposition, with diameter varying over
he nasal cycle. Sinus deposition is controversial but seems to be
ue to pressure difference between the sinus and nose [5]; it varies
ith individual anatomy and is proportional to ostial diameter; the
ptimal particle size to reach the sinuses may  be 0.7–10 m [6].
In oral inhalation, the guidelines identify deposition sites
ccording to particle size [7]. Particles with aerodynamic diam-
ter >5 m are deposited mainly in the oral cavity, larynx and
rachea; those with aerodynamic diameter 4–5 m,  in the bronchi;
nd those with aerodynamic diameter 0.5–4 m,  in the deep lung.
articles <0.5 m are too ﬁne to be deposited and get exhaled.
Ventilation parameters also affect deposition. Particle speed
s determined by the generator and inﬂuenced by the individual
atient. Rapid inspiration accelerates the particles and increases
eposition in the upper airway. Individual airway anatomy strongly
ffects inspiration hydraulics and thus deposition.
It follows that nasal nebulization is preferable for targeting the
asal cavities. A nasal plug should be used; in patients for whom
his is not feasible, a mask is preferable to a mouth end-piece.
Guideline 1
Nebulization should enable deposition over the entire nasal
cavity surface, including medial meatus – unlike sprays, with
which deposition is essentially anterior. Strong agreement.
. Aerosol generators
There are various ways of producing ENT aerosols. Two  cat-
gories may  be distinguished. Sprays are ready-to-use devices
lready containing the drug; nebulizers need to be prepared by
ntroducing the drug into the reservoir. Sprays are portable, for
nstantaneous dose delivery; nebulizers tend to be heavier and
equire several minutes’ inhalation.
Sprays produce large particles (10–150 m)  at high speed, with
eposition mainly in the anterior centimeters of the cavity [8];
he entire dose is deposited within the cavity. Nebulizers produce
lower and smaller particles (1–10 m),  with more distal depo-
ition [9–11]; they can target regions (e.g., sinus) not reached by
prays, with signiﬁcantly longer drug residence (1.2 h vs. 14 min)
10]. Even so, only 5-20% of the mass in the reservoir gets deposited
n the nasal cavity; the shortfall is due to a large residual quantityogy, Head and Neck diseases 131 (2014) 371–374
of drug left in the nebulizer and a large amount of aerosol lost to
the air during expiration.
There are three main types of nebulizers: pneumatic nebuliz-
ers use compressed air; ultrasonic nebulizers use high-frequency
piezoelectric quartz vibration; and mesh nebulizers use the vibra-
tion of a microperforated mesh. Pneumatic nebulizers have the
advantage that they can be used with any liquid preparation and
are robust and easy to maintain. Ultrasonic nebulizers do not work
with certain preparations: e.g., with high viscosity or in suspension.
Mesh nebulizers are subject to viscosity and surface tension effects,
but are silent in operation and small in size.
Some devices have additional functions to enhance upper air-
way deposition. The sonic function adds a sound-wave to the
aerosol to improve maxillary sinus penetration and deposition.
Studies on the operating principles of these devices go back to
the 1950s: the principle is to induce acoustic hyperpressure in
the ostium, displacing the air and aerosol toward the maxillary
sinuses. Several in-vitro studies on models of varying sophistica-
tion demonstrated the beneﬁt of introducing sound [12–14], but
only very recently has it been demonstrated in humans, in scinti-
graphic studies [10,15,16]. Sinus deposition is 3–5-fold greater [17]
than with a nebulizer without sonic boost.
The manosonic function is a derivative of this sonic function,
adding hyperpressure to create positive pressure in the nasal cavi-
ties; this is automatically applied in the nose at the exact moment
of swallowing, so as to transfer the aerosol toward the Eustachian
tube. Systems with this extra function are known as manosonic
aerosol generators.
Guideline 2
Nebulizers with additional sonic vibration are recom-
mended in rhinosinus pathology. Ultrasonic aerosols are
suitable for bronchopulmonary pathology. Strong agreement.
Guideline 3
Nasal plugs are to be preferred. Mouth end-pieces are
reserved to laryngeal and bronchopulmonary applications.
Strong agreement.
Guideline 4
Oro-nasal masks cause deposition on the face and within
the oral cavity and should be reserved to patients unable to
use a nasal plug. Strong agreement.
Guideline 5
Active substances should not be diluted for last-generation
nebulizers, as residual volume is slight. Relative agreement.Guideline 6
Nebulization time depends on drug volume, and should not
exceed 10 minutes. Strong agreement.
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Guideline 7
In the absence of studies of rhinosinus pathology, the
work group recommends nebulization of drugs with market
authorization in bronchopulmonary pathology: budesonide,
beclomethasone, tobramycin, colimycin. Relative agreement.
Guideline 8
In the absence of clinical efﬁcacy studies of drug associa-
tions in aerosol rhinosinus pathology, the work group advises
against nebulizing associations in a given session. Disagree-
ment.
Guideline 9
The work group advises against nebulizing oily prepara-
tions (risk of lipid pneumonia) or those containing sulﬁtes
(risk of bronchospasm) or other empiric preparations. Relative
agreement.
Guideline 10
The work group recommends nasal cavity lavage ahead of
nebulization. Relative agreement.
. Clinical studies
Clinical studies of nasal nebulization are few, and with small
ohorts. The ﬁrst prospective study, in 2001, reported fosfomycin
erosol nebulization 3 times per week for four weeks in 28 chronic
hinosinusitis (CRS) patients; symptoms and endoscopic aspect
mproved in 60% of patients, and posterior rhinorrhea in 88% [18].
he second prospective study, in double-blind versus placebo, ana-
yzed tobramycin nebulization in 20 CRS patients after failure of
edical and surgical treatment; patients received nebulization of
ither physiological saline or 80 mg  tobramycin three times per day
or four weeks. Symptoms (obstruction, pain, nasal mucosa edema,
osterior nasal discharge and secretion), quality of life and endo-
copic parameters were assessed at end of treatment and at four
eeks’ follow-up. Symptoms and quality of life showed signiﬁcant
mprovement (P < 0.05) in both arms; tobramycin nebulization was
ssociated with faster resolution of pain at two weeks (P < 0.05),
ith no signiﬁcant difference by 4 weeks. Tolerance was the same
n both arms (P < 0.05) but tobramycin induced nasal cavity con-
estion [19].
In 2002, Vaughan and Carvalho assessed the microbiological
mpact of antibiotic nebulization versus standard oral or intra-
enous administration in 42 patients undergoing sinus surgery for
RS, comparing cultures from sinus endoscopy samples at end of
reatment. Nasal obstruction and facial pain showed improvement
ith nebulization; nebulized antibiotic aerosol therapy resolved
nfection in 76% of cases [20]. Scheinberg and Otsuji, in the same
ear, reported a prospective study of antibiotic nebulization in 41
atients with exacerbated CRS resistant to surgical and medical
oral antibiotic) therapy. Treatment lasted 3-6 weeks; antibi-
tics comprised cefuroxim (285 mg  twice daily), ciproﬂoxacin
70 mg  twice daily) or tobramycin (90 mg  twice daily). Symptomsogy, Head and Neck diseases 131 (2014) 371–374 373
(obstruction, pain, rhinorrhea and malaise) improved with treat-
ment in 83% of cases [21].
In 2008, Videler et al. reported a double-blind prospective cross-
over study against placebo in 14 patients with exacerbated CRS
resistant to surgical and medical treatment, testing the efﬁcacy
of bacitracin/colimycin nebulization associated to oral levoﬂox-
acin. All patients received 500 mg  levoﬂoxacin twice daily for 2
weeks ahead of nebulization and, after randomization, received
8 days’ twice daily nebulization of either bacitracin/colimycin
(6.64 mg/5.12 mg/8 mL)  or physiological saline. Symptom severity
was self-assessed on VAS and quality of life on the SF36 question-
naire; efﬁcacy was assessed on nasal endoscopy. Facial pain was
reduced in both groups at end of study (P < 0.05); symptomatology
and quality of life were identical; endoscopy found no difference
between the two groups [22].
Guideline 11
Nebulization is recommended in purulent edematous rhi-
nosinusitis, subacute rhinosinusitis (4–12 weeks’ evolution)
and exacerbated chronic rhinosinusitis. Relative agreement.
Guideline 12
Nebulization is recommended in persistent postoperative
rhinosinus suppuration (> 1 month). Strong agreement.
Guideline 13
Two nebulizations per day should be prescribed for at least
seven days. Relative agreement.
Guideline 14
Audiometric monitoring is recommended in iterative rhino-
logic aminoside nebulization. Relative agreement.
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